Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dale M. Larson is active.

Publication


Featured researches published by Dale M. Larson.


Gynecologic Oncology | 1988

Recurrent cervical carcinoma after radical hysterectomy

Dale M. Larson; Larry J. Copeland; C. Allen Stringer; David M. Gershenson; John M. Malone; Creighton L. Edwards

The characteristics of recurrent carcinoma following radical hysterectomy and pelvic lymphadenectomy for cervical carcinoma are not well known. Disease recurrence was noted in 27 of 249 patients (11%) with stage IB cervical carcinoma who were treated with a primary surgical approach between January 1962 and December 1984. Fourteen recurrences (52%) occurred within 1 year of surgery, and 24 (89%) within 2 years. Patients with pelvic node metastases or adenocarcinoma had a significantly higher recurrence rate than did patients with negative nodes (33% vs 8%) or with squamous carcinoma (22% vs 8%). Seventeen patients (63%) had disease recurrence in the pelvis or vulva and 12 of these patients had recurrences within 1 year. Eight patients developed asymptomatic pelvic or vulvar recurrences, and all were diagnosed within 1 year. Ten patients (37%) developed recurrences outside the pelvis and 8 of these experienced recurrence after 1 year. Successful treatment after recurrence was independent of clinical or histopathologic parameters except site of recurrence. Eight of 15 patients (53%) who were treated with irradiation for a recurrence in the pelvis or vulva are free of disease 10 to 126 months (median, 48 months) after recurrence. Since irradiation can aid in salvaging patients with recurrent cervical carcinoma confined to the pelvis following radical surgery, clinical vigilance for this site of recurrence is emphasized.


Cancer | 1986

Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma: Potential for cure and preservation of reproductive capacity

David M. Gershenson; J. Taylor Wharton; Richard C. Kline; Dale M. Larson; John J. Kavanagh; Felix N. Rutledge

Two patients with metastatic dysgerminoma of the ovary were treated with a combination of etoposide, bleomycin, and cisplatin at The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Both patients achieved a complete remission. Patient 1 developed a massive recurrence in the para‐aortic lymph nodes 21 months after diagnosis and treatment with right salpingo‐oophorectomy alone. She received four cycles of chemotherapy and is free of disease 21 months from the start of chemotherapy. Patient 2 had Stage III dysgerminoma and a lymphangiogram positive for tumor in the para‐aortic lymph nodes. After surgery she received three cycles of chemotherapy and is free of disease 20 months from the start of chemotherapy. Both complete remissions were documented with second‐look laparotomy. Chemotherapy may be an alternative to radiotherapy for the treatment of metastatic dysgerminoma and should also be considered for selected patients with Stage I disease. A literature review further supports the conclusion that additional clinical trials might expand the indications for chemotherapy in patients with this disease.


Cancer | 1987

Prognostic factors in stage II endometrial carcinoma

Dale M. Larson; Larry J. Copeland; H. Stephen Gallager; J. Taylor Wharton; David M. Gershenson; Creighton L. Edwards; John M. Malone; Felix N. Rutledge

The rarity of Stage II endometrial carcinoma and variable treatment modalities have made the evaluation of prognostic factors difficult. Clinical, surgical, and pathologic characteristics were evaluated in 64 patients treated with whole pelvic irradiation and intracavitary radium followed by hysterectomy at The University of Texas M. D. Anderson Hospital and Tumor Institute from January 1965 to December 1983. Comparison of 5‐year actuarial survival rates revealed the following statistically significant categories: age, grade, depth of myometrial invasion, disease extent at surgery including lymph node metastases, and pelvic cytology. Race, weight, and cell type were not significant prognostic factors. Evaluation of prognostic factors at surgery includes pelvic and para‐aortic lymph node biopsies, omental biopsy, pelvic cytologic washings, and biopsy of any suspicious tissues. Patients with adverse prognostic factors are candidates for trials with adjuvant therapy.


Cancer | 1987

Nature of cervical involvement in endometrial carcinoma

Dale M. Larson; Larry J. Copeland; H. Steven Gallager; David M. Gershenson; Ralph S. Freedman; J. Taylor Wharton; Richard C. Kline

In patients with endometrial carcinoma the prognostic significance of clinical and histopathologic variants of cervical involvement is unknown. Fifty‐eight patients with endometrial carcinoma and cervical involvement diagnosed by gross examination or endocervical curettage are reviewed. Three clinicopathologic groups were identified: gross cervical involvement (10 patients), occult stromal invasion (25), and no evidence of stromal invasion (23). There were no differences in clinical, pathologic, surgical, or therapeutic characteristics. There was no significant difference in actuarial 5‐year survival rates between patients with gross cervical involvement (70%) and occult disease (65%). There was also no significant difference in survival rates among patients with occult cervical stromal invasion (67%). The presence of cervical involvement in endometrial carcinoma is an important prognostic factor. However, the extent of cervical involvement does not appear to be of significant prognostic value. Cancer 59:959‐962, 1987.


International Journal of Gynecology & Obstetrics | 1990

Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery

J.T. Soper; Dale M. Larson; Verda J. Hunter; Andrew Berchuck; Daniel L. Clarke-Pearson

The short gracilis myocutaneous flap derives its blood supply from terminal branches of the obturator artery, and the vascular pedicle derived from the medial femoral circumflex artery is sacrificed. Twenty-one short gracilis myocutaneous flaps were used for vulvovaginal reconstructions in 11 patients undergoing radical pelvic surgery: bilateral flaps in nine patients for neovaginal construction after pelvic exenterations, bilateral flaps in one patient for vulvovaginal reconstruction after radical vulvovaginectomy, and a unilateral flap in one patient for vulvovaginal reconstruction after radical vulvectomy with partial vaginectomy. Major complications consisted of bilateral flap necrosis occurring in one patient who had received preoperative irradiation to the vulva and groin combined with chemotherapy. Minor degrees of necrosis (less than 5%) and/or separation of vaginal suture lines occurred in five patients without marked loss of the flaps. Vaginal caliber and depth are excellent in ten patients (91%) after follow-up of 1-22 months. The short gracilis flap is an excellent alternative to the more bulky gracilis flap, which derives its blood supply from perforating branches of the femoral artery. Based on our experience, the short gracilis flap provides adequately vascularized tissue for vulvovaginal reconstruction in patients after radical pelvic surgery, but should not be used in patients who have received extensive groin irradiation.


Obstetrics & Gynecology | 1986

Central nervous system metastases in epithelial ovarian carcinoma

Dale M. Larson; Larry J. Copeland; Richard P. Moser; John M. Malone; David M. Gershenson; J. Taylor Wharton


Obstetrics & Gynecology | 1987

Stage ib cervical carcinoma treated with radical hysterectomy and pelvic lymphadenectomy: Role of adjuvant radiotherapy

Dale M. Larson; Stringer Ca; Larry J. Copeland; David M. Gershenson; John M. Malone; Felix N. Rutledge


Obstetrics & Gynecology | 1988

Diagnosis of recurrent cervical carcinoma after radical hysterectomy

Dale M. Larson; Larry J. Copeland; John M. Malone; C. Allen Stringer; David M. Gershenson; Creighton L. Edwards


Obstetrics & Gynecology | 1989

Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery.

John T. Soper; Dale M. Larson; Verda J. Hunter; Andrew Berchuck; Daniel L. Clarke-Pearson


Obstetrics & Gynecology | 1987

Ureteral assessment after radical hysterectomy.

Dale M. Larson; John M. Malone; Larry J. Copeland; David M. Gershenson; Richard C. Kline; C. Allen Stringer

Collaboration


Dive into the Dale M. Larson's collaboration.

Top Co-Authors

Avatar

David M. Gershenson

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Larry J. Copeland

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

John M. Malone

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

J. Taylor Wharton

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Creighton L. Edwards

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Felix N. Rutledge

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

C. Allen Stringer

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Richard C. Kline

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel L. Clarke-Pearson

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge